



Office de la Propriété

Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2318536 C 2009/11/17

(11)(21) **2 318 536**

(12) **BREVET CANADIEN**
CANADIAN PATENT

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 1999/11/23
(87) Date publication PCT/PCT Publication Date: 2000/06/15
(45) Date de délivrance/Issue Date: 2009/11/17
(85) Entrée phase nationale/National Entry: 2000/07/20
(86) N° demande PCT/PCT Application No.: US 1999/027796
(87) N° publication PCT/PCT Publication No.: 2000/033872
(30) Priorités/Priorities: 1998/11/25 (US60/109,952);
1999/03/30 (US60/126,794)


(51) Cl.Int./Int.Cl. *A61K 39/00* (2006.01),
A61K 39/104 (2006.01), *C07K 14/21* (2006.01)

(72) Inventeurs/Inventors:
FRANK, DARA W., US;
YAHAR, TIMOTHY L., US;
SAWA, TEIJI, US;
WIENER-KRONISH, JEANINE, US

(73) Propriétaires/Owners:
MCW RESEARCH FOUNDATION, INC., US;
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA,
US

(74) Agent: BORDEN LADNER GERVAIS LLP

(54) Titre : PROCEDE ET COMPOSITION POUR UNE IMMUNISATION AVEC L'ANTIGENE PSEUDOMONAS V
(54) Title: METHOD OF AND COMPOSITIONS FOR IMMUNIZATION WITH THE PSEUDOMONAS V ANTIGEN



(57) Abrégé/Abstract:

A method of inhibiting, moderating or diagnosing *Pseudomonas aeruginosa* infection is disclosed. In one embodiment, this method comprises inoculating a patient with an effective amount of PcrV antigen.




PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 39/00		A2	(11) International Publication Number: WO 00/33872
			(43) International Publication Date: 15 June 2000 (15.06.00)
(21) International Application Number: PCT/US99/27796	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).		
(22) International Filing Date: 23 November 1999 (23.11.99)			
(30) Priority Data: 60/109,952 25 November 1998 (25.11.98) US 60/126,794 30 March 1999 (30.03.99) US			
(71) Applicant: MCW RESEARCH FOUNDATION, INC. [US/US]; 8701 Watertown Plank Road, Milwaukee, WI 53226 (US).			
(72) Inventors: FRANK, Dara, W.; 5425 West Hayes Avenue, West Allis, WI 53219 (US). YAHR, Timothy, L.; 23 Seminary Hill Road, Hanover, NH 03784 (US). SAWA, Teiji; 1251 175th Avenue #6, San Francisco, CA 94122 (US). WIENER-KRONISH, Jeanine; 1908 16th Avenue, San Francisco, CA 94116 (US).			
(74) Agent: BAKER, Jean, C.; Quarles & Brady LLP, 411 East Wisconsin Avenue, Milwaukee, WI 53202-4497 (US).			

(54) Title: METHOD OF AND COMPOSITIONS FOR IMMUNIZATION WITH THE *PSEUDOMONAS V* ANTIGEN

(57) Abstract

A method of inhibiting, moderating or diagnosing *Pseudomonas aeruginosa* infection is disclosed. In one embodiment, this method comprises inoculating a patient with an effective amount of PcrV antigen.

METHOD OF AND COMPOSITIONS FOR IMMUNIZATION
WITH THE PSEUDOMONAS V ANTIGEN

5

STATEMENT REGARDING FEDERALLY SPONSORED
RESEARCH OR DEVELOPMENT

This invention was made with United States
government support awarded by the following agencies:

10 NIH/NIADA Grant Nos. R01 AI31665-08, K04 AI01289-04 and
R01 HL59239-02. The United States has certain rights in
this invention.

BACKGROUND OF THE INVENTION

15 *Pseudomonas aeruginosa* is an opportunistic bacterial
pathogen that is capable of causing fatal acute lung
infections in critically ill individuals (1). The
ability of the bacterium to damage the lung epithelium
has been linked with the expression of toxins that are
directly injected into eukaryotic cells via a type III-
20 mediated secretion and translocation mechanism (2, 3).

The proteins encoded by the *P. aeruginosa* type III
secretion and translocation apparatus demonstrate a high
level of amino acid identity with members of the *Yersinia*
Yop regulon (4-6). Of all the type III systems
25 discovered in Gram-negative bacteria, only *P. aeruginosa*

possesses a homologue to the *Yersinia* V antigen, PcrV (see 6 for review of type III systems). Homologous proteins to the secretion and translocation apparatus are encoded by both plant and animal pathogenic bacteria.

5 These organisms include human pathogens such as *Salmonella typhimurium*, *Shigella flexneri*, *Enteropathogenic E. coli*, *Chlamydia* spp., and plant pathogens such as *Xanthomonas campestris*, *Pseudomonas syringae*, *Erwinia amylovora* and *Ralstonia solanacearum*.

10 However, only *P. aeruginosa* and *Yersinia* encode the V antigen.

Yahr, et al., 1997, discloses the sequence of the operon encoding PcrV and compares the sequence to the LcrV protein. Thus, the amino acid sequence of PcrV is 15 known and is available under accession number AF010149 of GenBank.

SUMMARY OF THE INVENTION

The present invention involves methods and compositions developed from our observation that the 20 *Pseudomonas* V antigen can be used to protect animals from a lethal lung infection.

In one embodiment, the present invention is a method of inhibiting *Pseudomonas* infection comprising inoculating a patient with an effective amount of PcrV 25 antigen. In another embodiment, DNA encoding PcrV is used as a gene vaccine.

In one preferred embodiment, the antigen is expressed as a recombinant protein and used to immunize patients at risk.

Preferably, the patient is completely protected from 5 infection.

In another embodiment, the DNA encoding PcrV (called *pcrV*) or a DNA fragment may be used diagnostically to detect *P. aeruginosa* infection.

In another embodiment, the recombinant protein (rPcrV) 10 is used diagnostically to detect antibodies from patients. Patient antibody response to PcrV may be associated with prognosis. Therefore, in this embodiment the recombinant protein is used as a prognostic indicator by measuring the patient's antibody titer.

15 The present invention also provides a method for inhibiting a *Psudomonas* infection in an individual by contacting the individual with an effective amount of a PcrV inhibitor, in particular with a PcrV antibody, antibody derivative or fragment, or antibody mimic. PcrV antibodies, 20 antibody derivatives and antibody fragments are also provided.

It is an aim of the present invention to actively and passively immunize a patient against *Psudomonas* infection.

It is another aim of the present invention to 25 diagnostically detect the *P. aeruginosa* infection.

It is another aim of the present invention to diagnostically detect antibodies from *Psudomonas* patients.

The invention provides use of a systemically 30 administrable humanized or human PcrV antibody specific to PcrV antigen of *Pseudomonas aeruginosa* for treating or preventing *Pseudomonas aeruginosa* infection.

The invention also provides use of a pulmonarily administrable humanized or human PcrV antibody specific to PcrV antigen of *Pseudomonas aeruginosa* as a therapeutic agent for treating or preventing *Pseudomonas aeruginosa* infection.

Other aims, features and advantages of the present invention will become apparent to one of skill in the art after review of the specification, claims and drawings.

10

DESCRIPTION OF THE DRAWINGS

Figs. 1A and 1B are a stained gel (Fig. 1A) and Western blot (Fig. 1B) illustrating the phenotypic analysis of 15 PA103ΔpcrV.

Figs. 2A and 2B are a graph (Fig. 2A) and set of bar graphs (Fig. 2B) illustrating the survival and lung injury of *P. aeruginosa* parental and mutant strains.

Figs. 3A and 3B are a graph (Fig. 3A) and a set of bar graphs (Fig. 3B) illustrating the effect of immunization on 20 survival, lung injury, and bacterial colonization.

Fig. 4 is a graph of the number of animals surviving a challenge with 5×10^5 CFU/mouse of strain PA103 after 25 passive administration of polyclonal IgG specific for PcrV, ExoU, PopD or control IgG from an unimmunized animal.

Fig. 5 is a graph (Fig. 5A) and a set of bar graphs (Fig. 5B) illustrating survival and protection from lung injury by concomitant administration of IgG to different

WO 00/33872

PCT/US99/27796

bacterial antigens and bacterial challenge. One-way ANOVA for lung injury, $p=0.026$, and lung edema, $p<0.0005$.

DESCRIPTION OF THE INVENTION

We disclose herein that PcrV has a novel regulatory effect on expression of the type III secreted products, is involved in the translocation of type III toxins, and is the first antigen that protects against lung injury induced by *P. aeruginosa* infection. Vaccination against PcrV prior to the airspace instillation of anti-PcrV IgG not only ensured the survival of challenged animals but also decreased lung inflammation and injury caused by the bacteria.

LcrV, or the V antigen, is a multifunctional protein that regulates secretion/translocation of the Yop effector proteins and plays an extracellular role in pathogenesis by altering the host cytokine response to *Yersinia* infection (7-11). The only known homologue of this critical pathogenic factor is an extracellular protein encoded by *P. aeruginosa*, termed PcrV.

One embodiment of the present invention is a method of moderating or inhibiting a *Pseudomonas* infection by immunizing a patient with an effective amount of the PcrV antigen. By "effective amount" we mean an amount of PcrV antigen effective to show some moderation or inhibition of *Pseudomonas* infection as compared to control subjects or animals who have not been treated with the antigen.

WO 00/33872

PCT/US99/27796

By "moderating" we mean that infection is inhibited by at least fifty percent compared to a non-immunized animal. Preferably, infection is completely prevented. A quantitative assessment of infection would preferably 5 include the examination of the amount of bacteria in the bloodstream or pleural fluids and/or an examination of lung injury parameters. For example, the absence of bacteria in the blood stream or pleural fluids would indicate prevention of infection. A reduction in lung 10 injury parameters would indicate that infection is moderated.

Infection could be quantitatively assessed by several other clinical indicators, including the reduction of bacterial load in the sputum, blood or 15 pleural fluids, reduction in the size of the infiltrate, oxygenation improvement, reduction in the length of time on mechanical ventilation, reduction in fever and reduction in white blood cell count.

By "PcrV antigen" we mean that portion or fragment 20 of the PcrV protein that is necessary to invoke an immune response which prevents or moderates infection.

Currently, we have used the full-length PcrV protein as an antigen to induce protection. However, one of skill in the art can map the protective epitope on the 25 molecule. For example, we will be producing monoclonal antibodies and screening them for the antibodies that prevent cytotoxicity in tissue culture. Antibodies that prevent cytotoxicity will be tested in the acute lung

infection model for passive protection against infection.

Monoclonal antibodies generally recognize a small region of amino acids and when the amino acids are contiguous, the epitope can be defined to as few as 6-9 amino acids.

5 To define the epitope, monoclonal antibodies that protect against infection and cytotoxicity will be tested for binding to progressively smaller forms of recombinant PcrV. (By "recombinant PcrV" or "rPcrV" we mean the protein produced from a PcrV gene that has been placed 10 in a non-native host.) This should localize the region. At this point we will chemically synthesize amino acid stretches to define the epitope. These chemically synthesized epitopes can be attached to carrier molecules and used for immunization to determine if protection is 15 achieved. Alternatively, we can construct different clones of PcrV, produce and purify recombinant proteins, and test these antigens in immunization and challenge experiments.

Based on mapping studies performed with PcrV, we 20 predict that the epitope lies between amino acids 113 and 245.

The PcrV antigen may be most easily obtained by the method we used, a commercially available bacterial expression plasmid called pet16b from Novagen. The pcrV 25 gene was first cloned from the *P. aeruginosa* chromosome as part of an operon. The coding region was amplified and inserted into two different vectors. One vector is for expression from *P. aeruginosa* as shown in Fig. 1.

WO 00/33872

PCT/US99/27796

This is a vector from Herbert Schweizer (reference 19) which we modified to contain an appropriate promoter sequence such that PcrV expression is coordinately regulated with the rest of the delivery and intoxication 5 apparatus of the bacterium. The second plasmid, pET16b, is for expression and purification purposes from *E. coli*.

The advantage of this system is that we do not have to worry about contaminating *P. aeruginosa* proteins, the protein is produced in great abundance, and there is a 10 one-step purification process. In this situation the PcrV coding region is amplified to be cloned in frame with a histidine tag provided on the pET16b vector. The multiple histidine residues fused to the amino terminus of PcrV allow affinity chromatography using a nickel-NTA 15 column. Therefore, a preferable PcrV antigen is a recombinant version of the natural PcrV protein.

In another embodiment, human or humanized monoclonal or polyclonal antibodies to PcrV are administered to prevent or treat infections with *P. aeruginosa*. In 20 patients at high risk for *P. aeruginosa* infection, antibodies could be administered for prevention of infection. In addition, antibodies may be administered after the onset of infection to treat the infection. In this case, antibodies can be administered alone or in 25 combination with antibiotics. Administration of antibodies in conjunction with antibiotics may allow the administration of shorter courses or lower doses of

WO 00/33872

PCT/US99/27796

antibiotics, thereby decreasing the risk of emergence of antibiotic-resistant organisms.

We envision at least three types of hypothetical patients: (1) A healthy individual at risk of serious 5 injury or burn (fire fighter, military personnel, police) would be immunized with the vaccine by a methodology (either injection or intranasal) that would give long-lived protection. A booster would be given on admission (intramuscular injection) to the hospital after injury. 10 (2) A patient who is being subjected to mechanical ventilation. (3) A patient who has been genetically diagnosed with cystic fibrosis.

15 Immunization may be done systemically or intranasally. Immunization of these individuals would preferably start during normal vaccination procedures for other childhood diseases. We would predict long-lived protection with booster doses probably around ages 5 and 10.

20 In another embodiment, one would use DNA encoding the PcrV protein or the complement of this DNA to diagnostically detect *P. aeruginosa* infection. One would obtain the DNA sequence of the PcrV antigen at GenBank AF010149. The coding region for PcrV is at nucleotides 626-1510. One may also choose to use a fragment of this 25 coding region or complement of this fragment. A successful probe is one that will hybridize specifically to the PcrV DNA and not to other regions.

WO 00/33872

PCT/US99/27796

One would preferably use a hybridization probe of at least 40 continuous nucleotides within the antigen sequence or two primers of at least 25 continuous nucleotides within the sequence. One skilled in the art 5 would appreciate that many standard forms of nucleic acid diagnostic techniques would be suitable, for example, hybridization of the single-stranded 40 nucleotide probe to DNA or RNA extracted from a patient's sputum. In another example, patient's sputum would be used as a 10 source for bacterial DNA or RNA to serve as a template for the PCR or RT-PCR reaction, respectively.

One would also determine *Pseudomonas aeruginosa* infection in an individual by contacting a sample obtained from the individual with an antibody specific 15 for PcrV and correlating enhanced antibody binding as compared with a control sample with *Pseudomonas aeruginosa* infection in the individual.

In an additional embodiment, the DNA encoding PcrV is used as a gene vaccine using standard molecular 20 biological methods. For example, one could review the following references for techniques known to those of skill in the art: Davis, H.L., et al., "DNA vaccine for hepatitis B: Evidence for immunogenicity in chimpanzees and comparison with other vaccines," Proc. Natl. Acad. Sci. 93:7213-7218, 1996; Barry, M.A., et al., "Protection 25 against mycoplasma infection using expression-library immunization," Nature 377:632-635, 1995; Xiang, Z.Q., et al., "Immune responses to nucleic acid vaccines to rabies

WO 00/33872

PCT/US99/27796

virus," Virology 209:569-579, 1995. By "effective amount" of a gene vaccine, we mean an amount of vaccine effective to moderate or eliminate *Pseudomonas* infection or *Pseudomonas* infection symptoms.

5 The protein or antigen could also be used diagnostically to detect antibodies in patients and, thus, predict the patient's infection status. One would preferably contact a sample obtained from an individual suspected of *Pseudomonas* infection with the PcrV protein
10 or fragment thereof and detect protein/antibody binding. One would then correlate enhanced antibody binding (as compared with a control sample) with *Pseudomonas aeruginosa* infection in the individual.

One could also use the PcrV antibody or antibody
15 fragments therapeutically. Once the antibody is safe for human use, one could: (a) administer it systemically and (b) administer it into the lungs as either a preventative treatment or as a therapy. In order to use the PcrV antibody in humans, the antibody is preferably
20 "humanized". In general, once the monoclonal antibody is obtained the heavy and light chain variable regions are cloned. These cloned fragments are then inserted into a human antibody backbone (constant regions). Thus, we can control the class of antibody (IgG, IgA, etc.) in
25 addition to providing the binding specificity.

For use in the present invention, the PcrV antibody may be a monoclonal antibody or polyclonal. The antibodies may be human or humanized, particularly for

therapeutic applications. Antibody fragments or derivatives, such as an Fab, F(ab')₂ or Fv, may also be used. Single-chain antibodies, for example as described in Huston, *et al.* (*Int. Rev. Immunol.* 10:195-217, 1993) 5 may also find use in the methods described herein. By "effective amount" of the PcrV antibody or antibody fragment we mean an amount sufficient to moderate or eliminate *Pseudomonas* infection or infection symptoms.

In addition to PcrV antibodies and antibody 10 fragments, small molecule peptidomimetics or non-peptide mimetics can be designed to mimic the action of the PcrV antibodies in inhibiting or modulating *Pseudomonas* infection, presumably by interfering with the action of PcrV. Methods for designing such small molecule mimics 15 are well known (see, for example, Ripka and Rich, *Curr. Opin. Chem. Biol.* 2:441-452, 1998; Huang, *et al.*, *Biopolymers* 43:367-382, 1997; al-Obeidi, *et al.*, *Mol. Biotechnol.* 9:205-223, 1998). Small molecule inhibitors 20 that are designed based on the PcrV antibody may be screened for the ability to interfere with the PcrV-PcrV antibody binding interaction. Candidate small molecules exhibiting activity in such an assay may be optimized by methods that are well known in the art, including for example, *in vitro* screening assays, and further refined 25 in *in vivo* assays for inhibition or modulation of *Pseudomonas* infection by any of the methods described herein or as are well known in the art. Such small molecule inhibitors of PcrV action should be useful in

WO 00/33872

PCT/US99/27796

the present method for inhibiting or modulating a *Pseudomonas* infection.

In another aspect of the present invention, PcrV protein may be used to identify a PcrV receptor which may 5 be present in the host cells, particularly in human cells, more particularly in human epithelial cells or macrophages. Identification of a PcrV receptor allows for the screening of small molecule libraries, for example combinatorial libraries, for candidates that 10 interfere with PcrV binding. Such molecules may also be useful in a method to inhibit or modulate a *Pseudomonas* infection.

Our first attempts at receptor identification will be to use PcrV in pull-down experiments. PcrV will be 15 fused to glutathione S-transferase (GST) and attached to column matrix for affinity chromatography of solubilized cellular extracts. Proteins binding specifically to PcrV will be eluted and subjected to amino terminal sequencing for identification. In parallel experiments PcrV will be 20 subjected to yeast two-hybrid analysis. In this case PcrV is fused in frame with the DNA binding domain of Gal4. Once the clone is obtained it will be transformed into a suitable yeast host strain. The yeast strain containing the Gal4PcrV construct will be transformed 25 with a Hela cell cDNA bank cloned in frame with the Gal4 activation domain. Double transformants that complement the ability to utilize histidine and produce beta galactosidase (proteins that interact with PcrV) will be

analyzed genetically and at the nucleotide sequence level. In case the receptor is a cellular glycolipid we will utilize an overlay technique where glycolipids are separated by thin-layer chromatography and then probed 5 with radiolabeled bacteria. The binding to specific components will be monitored by autoradiography. Similarly, epithelial and macrophage proteins will be separated by SDS-PAGE, blotted onto nitrocellulose and overlaid with radiolabeled bacteria or labeled PcrV. 10 Again, the protein components to which the bacteria bind are then identified by autoradiography.

Pseudomonas species are known to infect a wide spectrum of hosts within the animal kingdom and even within the plant kingdom. As will be apparent to one of 15 ordinary skill in the art, the compositions and methods disclosed herein may have use across a wide range of organisms in inhibiting or modulating diseases or conditions resulting from infection by a *Pseudomonas* species. The compositions and methods of the present 20 invention are described herein particularly for application to *Pseudomonas aeruginosa* but it is well within the competence of one of ordinary skill in the art to apply the methods taught herein to other species.

EXAMPLES

25 1. Role of PcrV in Cytotoxicity

To determine the role of PcrV in type III-mediated regulation/secretion, we constructed a nonpolar allele of

WO 00/33872

PCT/US99/27796

PcrV and used the construct to replace the wild-type allele in *P. aeruginosa* strain PA103, a strain that is highly cytotoxic *in vitro* (3) and causes lung epithelial damage *in vivo* (12, 13). Cytotoxicity and lung injury 5 are due to the production of a specific cytotoxin, ExoU (3).

PA103ΔpcrV was characterized by the expression of several extracellular products that are secreted by the *P. aeruginosa* type III system which include the ExoU 10 cytotoxin (3), PcrV (5), and a protein required for the translocation of toxins, PopD (14). SDS-polyacrylamide gel electrophoresis of concentrated culture supernatants indicated that the parental strain, PA103 is induced for production and secretion of the type III proteins by 15 growth in medium containing a chelator of calcium, nitrilotriacetic acid (NTA) (Fig. 1). When an expression clone encoding PcrV was provided in *trans* in the parental strain, extracellular protein production in response to the presence or absence of NTA is normal. PA103ΔpcrV 20 exhibits a calcium blind phenotype; extracellular protein production is strongly induced in both the presence and absence of NTA. These results suggest that the secretory system is fully functional but deregulated. This deregulated phenotype is in contrast to the calcium 25 independent phenotype reported for an LcrV defective strain which fails to produce the extracellular Yops, grows at 37°C regardless of the presence or absence of calcium, and shows only partial induction of the Yops.

(7). Complementing PA103 Δ pcrV with a clone expressing wild-type PcrV restored normal regulation of extracellular protein production in response to NTA induction.

5 To test the contribution of PcrV to *P. aeruginosa* pathogenesis, two infection models were used. In an *in vitro* model the parental and several mutant derivative strains were compared for their ability to cause cytotoxicity in a CHO cell infection assay (3). The 10 negative controls in this experiment included PA103 $popD::\Omega$, which has been previously shown to be defective in the translocation of type III virulence determinants (14) and PA103 Δ exoU, which is non-cytotoxic due to the absence of ExoU production (3, 15).

15 After a 3 hour infection, CHO cells were unable to exclude trypan blue with the wild-type and Δ pcrV strain complemented with a plasmid construct expressing PcrV. Staining did not occur when CHO cells were infected with the negative control strains or with PA103 Δ pcrV (data not 20 shown). These results suggest that PcrV expression is required for cytotoxicity. Purified recombinant PcrV was not cytotoxic when added exogenously to tissue culture cells. Since secretion of the type III proteins required for translocation was unaffected by the deletion of pcrV 25 (Fig. 1A and B), PA103 Δ pcrV appears to be defective in ExoU translocation.

Figs. 1A and 1B are a stained gel (Fig. 1A) and Western blot (Fig. 1B) illustrating the phenotypic

analysis of PA103 Δ pcrV. The parental and Δ pcrV derivatives, with and without a plasmid expressing PcrV in *trans*, were grown in the absence or presence of the inducer of type III secretion in *P. aeruginosa*, 5 nitrilotriacetic acid (NTA). The extracellular protein profile (Fig. 1A) was analyzed on a SDS-polyacrylamide gel (10%) stained with Coomassie blue. The migration of the *P. aeruginosa*-encoded type III proteins is indicated to the left and the migration of molecular weight markers 10 is indicated on the right. Fig. 1B is a Western blot of a duplicate gel using antibodies specific for ExoU, PcrV, and PopD and 125 I-Protein A to detect bound IgG.

Wild-type and mutant *P. aeruginosa* strains were tested in an acute lung infection model using low and 15 high challenge doses of bacteria. Survival measurements indicated that PcrV and PopD were required to induce a lethal infection (Fig. 2A). In experiments utilizing three independent measurements of lung injury (the flux of labeled albumin from the airspaces of the lung to the 20 bloodstream, the flux of labeled albumin from the airspaces of the lung to the pleural fluids, and the wet/dry ratio, which measures lung edema) the degree of injury caused by PA103 Δ pcrV, the vector control strain (PA103 Δ pcrVpUCP18), and PA103 $popD::\Omega$ were no different 25 than the uninfected control animals (Fig. 2B).

Complementation of PA103 Δ pcrV with pcrV in *trans* restored lung injury levels to those measured with the parental strain, PA103. Taken together these data indicate that

WO 00/33872

PCT/US99/27796

PcrV expression is required for virulence of *P. aeruginosa* in the acute lung infection model and that part of the function of PcrV appears to be linked to the ability to translocate type III effector proteins into 5 eukaryotic cells.

Figs. 2A and 2B are a graph (Fig. 2A) and set of bar graphs (Fig. 2B) illustrating the survival and lung injury of *P. aeruginosa* parental and mutant strains. Referring to Fig. 2A, mice were challenged with 5×10^5 10 cfu of each of the indicated strains and survival was monitored for one week. Referring to Fig. 2B, lung injury was assessed by the flux of labeled albumin from the airspaces of the lung to the blood (lung epithelial injury), to the pleural fluid (pleural fluid) or by 15 measuring the wet/dry ratio (lung edema). Two bacterial infectious doses were used as denoted by the solid and striped bars. Significant differences ($*p<0.001$) between control and test groups was determined by one-way ANOVA and Dunnet multiple comparison tests. The following 20 abbreviations were used: PA103, parental wild-type strain; $\Delta pcrV$, PA103 $\Delta pcrV$; $\Delta pcrVpUCPpcrV$, PA103 $\Delta pcrV$ complemented with a plasmid expressing PcrV; $\Delta pcrVpUCP$, PA103 $\Delta pcrV$ with a vector control; $popD::\Omega$, PA103 $popD::\Omega$, a translocation defective strain.

25 2. Immunization with PcrV

To determine whether immunization with PcrV protected animals from a lethal lung infection, recombinant PcrV (rPcrV) or ExoU (rExoU) were purified as

histidine-tagged fusion proteins and used as antigens. Mice were immunized and subsequently challenged via their airspaces with a lethal dose of strain PA103. When survival was measured, both vaccines protected the mice 5 (Fig. 3A). When lung injury was assessed, only PcrV vaccinated animals had significantly less epithelial damage and lung edema (Fig. 3B). Animals immunized with the PcrV vaccine also had significantly fewer bacteria in their lungs, suggesting that a blockade of the 10 *Pseudomonas V* antigen may facilitate rapid clearance of bacteria from the lung, protecting the animals from severe epithelial injury (Fig. 3B).

Figs. 3A and 3B are a graph (Fig. 3A) and a set of bar graphs (Fig. 3B) illustrating the effect of 15 immunization on survival, lung injury, and bacterial colonization. Referring to Fig. 3A, mice were immunized (PcrV, n=10; ExoU, n=5; control, n=10) as indicated and challenged with strain PA103 at 5×10^5 CFU/animal. The percent of surviving animals was determined for one week; 20 p<0.05 by the Mantel-Cox log rank test. Referring to Fig. 3B, lung injury assessment and bacterial colonization of vaccinated animals 4 hours after installation of PA103. Lung epithelial injury, lung edema, and bacterial burden; PcrV, n=9; ExoU, n=4; and 25 control, n=8. The final number of bacteria in the lung is indicated as the number on the Y axis $\times 10^4$ CFU. Significant differences (*) for lung injury (p<0.01), lung edema (p<0.05), and bacterial numbers (p<0.05) as

WO 00/33872

PCT/US99/27796

determined by Dunnet multiple comparison test. One-way ANOVA for lung injury, $p=0.0005$; lung edema, $p=0.0437$; bacterial burden, $p=0.0075$.

To determine whether therapeutic intervention was possible, mice were passively immunized with preimmune rabbit IgG or rabbit IgG specific for rPcrV, rExoU, or rPopD one hour prior to airspace instillation of PA103 at a concentration of 5×10^5 CFU/mouse. Antibodies to rPcrV provided complete protection to a lethal infection (Fig. 4). Anti-rExoU IgG provided partial survival, which was significantly different from the administration of control IgG, although all the surviving animals appeared severely ill during the trial. Survival was not improved by the passive transfer of antibodies to another of the type III translocation proteins, PopD. From these results we conclude that antibodies to PcrV are highly protective in the acute lung infection model and that PcrV may be exposed on the bacterial surface or in a soluble form that is available for antibody-antigen interactions.

Fig. 4 is a graph of the number of animals surviving a challenge with 5×10^5 CFU/mouse of strain PA103. Animals were pretreated with 100 μ g of immune IgG or control IgG from an unimmunized rabbit (rPcrV, preimmune serum). N=10 for each group; * $p<0.05$ versus control group for treatment with anti-PcrV and anti-ExoU IgG preparations by Mantel-Cox log rank test.

If PcrV is accessible for neutralization, then concomitant administration of the bacterial inoculum with anti-rPcrV IgG should completely protect against lung injury and lethality. IgG preparations were mixed with 5 the inoculum (10-fold higher dose than the lethal inoculum) prior to instillation of the bacteria into the lung and survival was measured. Only anti-rPcrV IgG was protective against this extreme infection (Fig. 5A). Lung injury was measured in animals infected with the 10 normal lethal dose of 5×10^5 bacteria. The efflux of labeled albumin from the airspaces of the lung was only 3% more than uninfected controls (Fig. 5B) after co-administration of anti-rPcrV IgG. The decreased efflux of labeled protein from the lung to the pleural fluids 15 was the same as the uninfected controls when anti-PcrV was included with the inoculum. Curiously lung edema, as measured by the wet/dry ratio, was significantly reduced by the addition of either anti-rPcrV or anti-rPopD. (Fig. 5B). Thus, the concomitant administration of anti- 20 rPcrV IgG with the bacteria was even more effective in normalizing all the lung injury parameters than vaccination. These data support the accessibility of PcrV for antibody-mediated neutralization and document a clinically relevant decrease in lung injury; antibodies 25 to PcrV may serve as therapeutic reagents in the treatment of severe nosocomial pneumonia caused by *Pseudomonas aeruginosa*.

Fig. 5 is a graph (Fig. 5A) and a set of bar graphs (Fig. 5B) illustrating survival and protection from lung injury by concomitant administration of IgG and bacterial challenge. IgG (5 µg) was mixed with either 5×10^6 (for 5 survival assays, n=10 per group) or 5×10^5 (for the measurement of lung injury, n=4 to 6 animals per group) *P. aeruginosa* strain PA103. This mixture was instilled into the lungs and survival (Fig. 5A) or lung injury (Fig. 5B) was assessed. For survival, *p<0.05 versus 10 control IgG for anti-PcrV by the Mantel-Cox log rank test; for lung epithelial injury and lung edema *p<0.05 versus control IgG by Dunnet multiple comparison test. One-way ANOVA for lung injury, p=0.026, and lung edema, p<0.0005.

15 In acute *P. aeruginosa* infections, the net effect of type III-mediated intoxication may be to promote the dissemination of the bacterium beyond the epithelium leading to infection of the pleural fluids, spleen, liver, and bloodstream. Bloodborne infections with *P. 20 aeruginosa* from either acute ventilator-associated pneumonia or from burn wound infections can result in a 40-80% mortality rate in spite of aggressive antibiotic treatment (16). PcrV must be a component of the type III translocation complex in *P. aeruginosa*, as mutants 25 defective in the production of this protein are unable to intoxicate CHO cells or cause lung epithelial injury even though they are able to produce and secrete the type III effectors and proteins required for translocation.

Unlike PopD, which is also necessary for translocation, PcrV is accessible for antibody-mediated neutralization suggesting that antibodies may be useful therapeutic agents in acute infections.

5 3. Methods for Examples 1 and 2

Construction of a nonpolar insertion in PcrV and complementation. A 5.0-kb EcoRI-NsiI restriction fragment encoding *pcrGVHpopBD* and flanking sequences was cloned into the allelic replacement vector pNOT19 (17).
10 Two *NotI* sites (one within *pcrG* and one within *popB*) were removed from the inserted sequences by using the Sculptor mutagenesis system (Amersham). An internal *SstI* restriction fragment was deleted from *pcrV*, resulting in an in-frame deletion of residues 17-221 (pNOT Δ *pcrV*). To
15 select for integration of the plasmid, a gene encoding tetracycline resistance (*TcQ*) was cloned into the *HindIII* site of the vector (pNOT Ω *pcrV*). The MOB cassette (17) was added as a *NotI* fragment. Selection of merodiploids, resolution of plasmid sequences, and confirmation of
20 allelic replacement was performed as previously described (18). A shuttle plasmid (pUCP, 19) was used to construct a clone to complement the *pcrV* deletion. The coding sequence for PcrV was amplified and cloned behind the control of the ExoS promoter region (20). The
25 transcription of ExoS is coordinately regulated with the operons that control type III secretion and translocation in *P. aeruginosa* (2). The nucleotide sequence was

confirmed for each DNA construct involving site specific mutagenesis, PCR amplification, or in-frame deletion.

SDS-PAGE and Western blot analysis of secreted products. *P. aeruginosa* were grown under inducing (+NTA) or non-inducing conditions (-NTA) for expression of the type III secreted products (18). Cultures were harvested based on optical density measurements at 540 nm and supernatant fractions were concentrated by the addition of a saturated solution of ammonium sulfate to a final concentration of 55%. Each lane of an SDS-polyacrylamide gel (11%) was loaded with 3 μ l of a 20-fold concentrated supernatant and stained with Coomassie blue. An identical gel was subjected to Western blot analysis as previously described (3-5) using a cocktail of rabbit antisera, which specifically recognizes ExoU, PopD, and PcrV. Protein A labeled with 125 I was used as a secondary reagent to identify bound IgG.

Infection models and lung injury assessments.

Chinese Hamster Ovary cells (CHO) were used in an *in vitro* infection model designed to measure cytotoxicity and type III translocation (21). Briefly, a bacterial inoculum was prepared in tissue culture medium without serum. CHO cells, which were propagated in serum containing medium, were washed and infected with various *P. aeruginosa* strains at a multiplicity of infection of 5:1. Cultures were incubated under tissue culture conditions for 3 hours (37°C, 5% CO₂), washed, and stained with trypan blue. Permeability to the dye was determined

WO 00/33872

PCT/US99/27796

from phase contrast photographs. Infection with the parental strain PA103, which expresses ExoU, results in trypan blue staining of approximately 80% of the monolayer after 3 hours of incubation and complete 5 destruction of the monolayer at 4-5 hours of incubation. Mouse infections and assessment of lung injury was performed as previously described (16). Briefly, male 8- to 12-week old pathogen-free BALB/c mice were purchased from Simonsen Laboratories (Gilroy, CA) and housed in 10 barrier conditions. The mice were briefly anesthetized with inhaled Metofane (methoxyflurane, Pitman-Moore, Mundelein, IL) and placed supine, at an angle of approximately 30°. Fifty microliters of the bacterial inoculum was instilled slowly into the left lobe using a 15 modified 24 gauge animal feeding needle (Popper & Sons, Inc., New Hyde Park, NY) inserted into the trachea via the oropharynx. When lung injury assessments were measured, 0.5 μ Ci of ^{131}I -labeled human serum albumin (Merck-Frosst, Quebec, Canada), 0.05 μ g of anhydrous 20 Evans blue in ml of Ringer's lactate with 5% mouse albumin were added to the instillate. After 4 hours of infection, the mice were anesthetized, blood was collected by a carotid arterial puncture and median sternotomies were performed. The lungs, pleural fluids, 25 tracheas, oropharynxes, stomachs, and livers were harvested, and the radioactivity was measured. The percentage of radioactive albumin that left the instilled lungs and entered the circulation or the pleural fluid

was calculated by multiplying the counts measured in the terminal blood samples (per ml) times the blood volume (body weight X 0.07). The wet-dry ratios of the lungs were determined by adding 1 ml of water to the lungs and 5 homogenizing the mixture. Homogenates were placed in preweighed aluminum pans and dried to constant weight in an 80°C oven for three days. Lung homogenates were also sequentially diluted and plated on sheep blood agar for quantitative assessment of bacteria.

10 Production of rabbit antiserum to PcrV, PopD, and ExoU. rPcrV, rPopD, and rExoU were produced as histidine tagged fusion proteins in pET16b and purified by nickel chromatography as previously described (22). Rabbits were injected intradermally (10 sites) with 300 µg of 15 recombinant protein emulsified in Freund's complete adjuvant, boosted with antigen in Freund's incomplete adjuvant, and periodically bled at 7 day intervals. For passive immunization, the IgG fraction was isolated using Protein A column chromatography (Pierce Chemicals, 20 Rockford, IL). Mice were injected with 100 µg IgG (intraperitoneal injection) 1 hour before challenge with 5 x 10⁵ CFU of strain PA103. For active immunization with rPcrV and rExoU, endotoxin was removed from protein preparations by extraction with 1% Triton^{*} X-114 (23). 25 Following the extractions, Triton X-114 was removed by Sephadryl^{*} S-200 chromatography. All vaccine preparations contained less than 1 ng of endotoxin per 40 µg of recombinant protein as determined by using a limulus

*Trade-mark

amebocyte lysate assay (BioWhittaker, Walkersville, MD).
BALB/c mice were injected subcutaneously with 10 µg of
recombinant proteins in Freund's complete adjuvant. At
day 30 the mice were boosted with an additional 10 µg of
5 antigen in Freund's incomplete adjuvant. On day 51 the
mice were challenged by instillation of *P. aeruginosa*
into their left lungs.

4. Synthesis of Monoclonal Antibodies

Mice were immunized with 10 µg of purified, LPS-
10 free, recombinant PcrV in Freund's complete adjuvant and
boosted two weeks later with the same dose of antigen
emulsified in Freund's incomplete adjuvant.

Immunizations were performed subcutaneously. Spleens
were harvested from mice one week after booster doses of
15 PcrV in Freund's incomplete adjuvant.

A single spleen was placed in 5 ml of tissue culture
medium without serum, cut into pieces and gently
homogenized. Large pieces of tissue were allowed to
settle from the homogenate and the supernatant, single-
20 cell suspension was removed and subjected to
centrifugation at 1200 rpm for 10 minutes. The pelleted
cells were resuspended in 10 ml of a solution to lyse red
blood cells for 5 minutes and subsequently underlaid with
10 ml of fetal bovine serum. The material was
25 centrifuged at 1200 rpm for 8 minutes, the supernatant
was discarded and the cells were suspended in 30 ml of
medium.

Spleenic cells and myeloma cells (P3x63Ag8.653) were harvested by centrifugation at 1200 rpm for 10 minutes, and each pellet was separately suspended in 10 ml of tissue culture medium. 10^6 spleen cells and 2×10^5 myeloma cells were mixed and pelleted together by centrifugation at 1200 rpm for 6 minutes. The supernatant was removed by aspiration and 1 ml of 35% polyethylene glycol (PEG) was added. The cells were suspended in this solution gently and centrifuged at 1000 rpm for 3 minutes. In some experiments centrifugation was eliminated.

Exactly 8 minutes after the addition of PEG, 25 ml of medium was added and the cells were gently resuspended. Following a 5 minute 1200 rpm centrifugation step, the cell pellet was suspended at a density of 1×10^6 per ml in 30% conditioned medium and 70% complete medium (with serum). The cells were incubated overnight at 37°C. The next day the cells were harvested by centrifugation and suspended in 200 ml of 30% conditioned medium and 70% complete medium with hypoxanthine, aminopterin and thymidine (HAT).

Approximately 0.2 ml of this cell suspension was added per well to ten 96-well plates (12 ml per 96 well plate). The density of the remaining cells was adjusted to 2.5×10^5 per ml and the cells were plated in the 96 well format. Plates were screened microscopically for single colonies and supernatants were subsequently tested for antibody production by enzyme-linked immunosorbent

WO 00/33872

PCT/US99/27796

assay using recombinant PcrV as the antigen. Clones producing antibodies reactive to PcrV were subcultured to larger culture dishes and then isotyping.

The binding of antibodies was tested in an enzyme linked immunosorbent assay using recombinant PcrV as the antigen (histidine-tagged protein) coating the wells. Monoclonal antibodies were also tested in Western blot reactions using a *P. aeruginosa* supernatant containing native PcrV without the histidine tag.

4. References

1. Wiener-Kronish, J.P., Sawa, T., Kurahashi, K., Ohara, M., and Gropper, M.A., "Pulmonary edema associated with bacterial pneumonia," *Pulmonary Edema* (eds Matthay, M.A. and Ingbar, D.H.) pp. 247-267 (Marcel Dekker, Inc., New York, 1998).
2. Frank, D.W., "The exoenzyme S regulon of *Pseudomonas aeruginosa*," *Mol. Microbiol.* 26:621-629 (1997).
3. Finck-Barbançon, V., *et al.*, "ExoU expression by *Pseudomonas aeruginosa* correlates with acute cytotoxicity and epithelial injury," *Mol. Microbiol.* 25:547-557 (1997).
4. Yahr, T.L., Goranson, J., and Frank, D.W., "Exoenzyme S of *Pseudomonas aeruginosa* is secreted by a type III pathway," *Mol. Microbiol.* 22:991-1003 (1996).
5. Yahr, T.L., Mende-Mueller, L.M., Friese, M.B., and Frank, D.W., "Identification of type III secreted products of the *Pseudomonas aeruginosa* exoenzyme S regulon," *J. Bacteriol.* 179:7165-7168 (1997).
6. Hueck, C.J., "Type III protein secretion systems in bacterial pathogens of animals and plants," *Microbiol. Mol. Biol. Rev.* 62:379-433 (1998).
7. Skrzypek, E. and Straley, S.C., "Differential effects of deletion in *lcrV* on secretion of V antigen, regulation of the low-Ca²⁺ response, and virulence of *Yersinia pestis*," *J. Bacteriol.* 177:2530-2542 (1995).
8. Nakajima, R. and Brubaker, R.R., "Association between virulence of *Yersinia pestis* and suppression of gamma interferon and tumor necrosis factor alpha," *Infect. Immun.* 61:23-31 (1993).
9. Nakajima, R., Motin, V.L., and Brubaker, R.R., "Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization," *Infect. Immun.* 63:3021-3029 (1995).
10. Nedialkov, Y.A., Motin, V.L., and Brubaker, R.R., "Resistance to lipopolysaccharide mediated by the *Yersinia pestis* V antigen-polyhistidine fusion peptide: amplification of interleukin-10," *Infect. Immun.* 63:1196-1203 (1997).
11. Nilles, M.L., Fields, K.A., and Straley, S.C., "The V antigen of *Yersinia pestis* regulates Yop vectorial targeting as well as Yop secretion through effects

on YopB and LcrG," J. Bacteriol. 180:3410-3420 (1998).

12. Kudoh, I., Wiener-Kronish, J.P., Hashimoto, S., Pittet, J.-F., and Frank, D.W., "Exoprotein secretions of *Pseudomonas aeruginosa* strains influence severity of alveolar epithelial injury," Am. J. Physiol. 267:L551-L556 (1994).

13. Apodaca, G., et al., "Characterization of *Pseudomonas aeruginosa*-induced MDCK cell injury: glycosylation-defective host cells are resistant to bacterial killing," Infect. Immun. 63:1541-1551 (1995).

14. Yahr, T.L., Vallis, A.J., Hancock, M.K., Barbieri, J.T., and Frank, D.W., "ExoY, a novel adenylate cyclase secreted by the *Pseudomonas aeruginosa* type III system," Proc. Natl. Acad. Sci. USA, in press (1998).

15. Finck-Barbançon, V., Yahr, T.L., and Frank, D.W., "Identification and characterization of SpcU, a chaperone required for efficient secretion of the ExoU cytotoxin," J. Bacteriol., in press (1998).

16. Sawa, T., Corry, D.B., Gropper, M.A., Ohara, M., Kurahashi, K., and Wiener-Kronish, J.P., "IL-10 improves lung injury and survival in *Pseudomonas aeruginosa* pneumonia," J. Immunol. 159:2858-2866 (1997).

17. Schweizer, H.P., "Allelic exchange in *Pseudomonas aeruginosa* using novel ColE1-type vectors and a family of cassettes containing a portable *oriT* and the counter-selectable *Bacillus subtilis* *sacB* marker," Mol. Microbiol. 6:1195-1204 (1992).

18. Frank, D.W., Nair, G., and Schweizer, H.P., "Construction and characterization of chromosomal insertional mutations of the *Pseudomonas aeruginosa* exoenzyme S trans-regulatory locus," Infect. Immun. 62:554-563 (1994).

19. Schweizer, H.P., "Escherichia-Pseudomonas shuttle vectors derived from pUC18/19," Gene 97:109-112 (1991).

20. Yahr, T.L., Hovey, A.K., Kulich, S.M., and Frank, D.W., "Transcriptional analysis of the *Pseudomonas aeruginosa* exoenzyme S structural gene," J. Bacteriol. 177:1169-1178 (1995).

21. Vallis, A.J., Yahr, T.L., Barbieri, J.T., and Frank, D.W., "Regulation of ExoS production by *Pseudomonas*

aeruginosa in response to tissue culture conditions," Infect. Immun. submitted.

22. Yahr, T.L., Barbieri, J.T., and Frank, D.W., "Genetic relationship between the 53- and 49-kilodalton forms of exoenzyme S from *Pseudomonas aeruginosa*," J. Bacteriol. 178:1412-1419 (1996).
23. Aidi, Y. and Pabst, M.J., "Removal of endotoxin from protein solutions by phase separation using Triton X-114," J. Immunol. Methods 132:191-195 (1990).

CLAIMS:

1. Use of an effective amount of PcrV antigen from *Pseudomonas aeruginosa* for inhibiting a *Pseudomonas aeruginosa* infection in a patient.
2. The use of claim 1 wherein the PcrV antigen is a recombinant PcrV protein.
3. The use of claim 1 wherein the PcrV antigen is a fragment of a PcrV protein from *Pseudomonas aeruginosa*, said fragment inducing an immune response specific to a PcrV antigen.
4. The use of claim 1 wherein DNA encoding PcrV is used as a gene vaccine.
5. The use of claim 4 wherein the DNA encodes a fragment of the PcrV protein, said fragment inducing an immune response specific to a PcrV antigen.
6. The use of claim 1 wherein the patient is a human patient.
7. Use of an effective amount of a gene vaccine encoding PcrV antigen from *Pseudomonas aeruginosa* for inhibiting *Pseudomonas aeruginosa* infection in a patient.
8. The use of claim 7 wherein the gene vaccine encodes an entire PcrV protein from *Pseudomonas aeruginosa*.
9. The use of claim 7 wherein the gene vaccine encodes a fragment of the Pcr protein, wherein the fragment induces an immune response specific to a PcrV antigen.
10. The use of claim 7 wherein the patient is a human patient.

11. Use of a systemically administrable PcrV antibody specific to PcrV antigen of *Pseudomonas aeruginosa* for treating or preventing *Pseudomonas aeruginosa* infection.
12. Use of a pulmonarily administrable PcrV antibody specific to PcrV antigen of *Pseudomonas aeruginosa* as a therapeutic agent for treating or preventing *Pseudomonas aeruginosa* infection.
13. Use of an effective amount of PcrV antigen from *Pseudomonas aeruginosa* for treating a *Pseudomonas aeruginosa* infection in a patient.




FIG. 1





FIG. 2






FIG. 4




FIG. 5

